Patents by Inventor Joseph Senn
Joseph Senn has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).
-
Publication number: 20220265857Abstract: This disclosure provides improved lipid-based compositions, including lipid nanoparticle compositions, and methods of use thereof for delivering agents in vivo including nucleic acids and proteins. These compositions are not subject to accelerated blood clearance and they have an improved toxicity profile in vivo.Type: ApplicationFiled: January 25, 2022Publication date: August 25, 2022Applicant: ModernaTX, Inc.Inventors: Gilles Besin, Stephen Hoge, Joseph Senn, Kerry Benenato, Staci Sabnis
-
Publication number: 20220125899Abstract: The present application is related to a method of treating a cancer by administering to a human subject multiple doses of a mRNA cancer vaccine formulated as a lipid nanoparticle wherein the cancer vaccine comprises one or more mRNAs each having one or more open reading frames encoding 3-50 peptide epitopes, and wherein each of the peptide epitopes are portions of personalized cancer antigens or portions of cancer hotspot antigens. The present application further relates to a method of treating cancer by combining anti-cancer immunotherapy with the administration of the aforementioned mRNA cancer vaccine.Type: ApplicationFiled: November 7, 2019Publication date: April 28, 2022Applicant: ModernaTX, Inc.Inventors: Ted Ashburn, Kristen Hopson, Karen Keating, Joseph Senn, Christine Swenson, Benjamin Breton, Shan Zhong, Maija Garnaas
-
Patent number: 11285222Abstract: This disclosure provides improved lipid-based compositions, including lipid nanoparticle compositions, and methods of use thereof for delivering agents in vivo including nucleic acids and proteins. These compositions are not subject to accelerated blood clearance and they have an improved toxicity profile in vivo.Type: GrantFiled: October 11, 2019Date of Patent: March 29, 2022Assignee: ModernaTX, Inc.Inventors: Gilles Besin, Stephen Hoge, Joseph Senn, Kerry Benenato, Staci Sabnis
-
Patent number: 10962330Abstract: A device and method for aligning a sighting device with a reference. The device includes features conforming to an industry standard for attaching accessories to a firearm. The device contains features which allow the device to be leveled relative to a removable level. A sighting device may be attached to the device using the industry standard features. Once attached, the sighting device may then be aligned using either the removable level or an external reference. Once the sighting device is secured in its mount, the mounted sight may then be installed and removed from one or more devices without its calibrated orientation being altered.Type: GrantFiled: May 10, 2018Date of Patent: March 30, 2021Assignee: Inventure Engineering and Machine, LLCInventor: Anthony Joseph Senn
-
Publication number: 20200206362Abstract: This disclosure provides improved lipid-based compositions, including lipid nanoparticle compositions, and methods of use thereof for delivering agents in vivo including nucleic acids and proteins. These compositions are not subject to accelerated blood clearance and they have an improved toxicity profile in vivo.Type: ApplicationFiled: October 11, 2019Publication date: July 2, 2020Applicant: Moderna TX, Inc.Inventors: Gilles Besin, Stephen Hoge, Joseph Senn, Kerry Benenato, Staci Sabnis
-
Patent number: 10556018Abstract: This disclosure provides improved lipid-based compositions, including lipid nanoparticle compositions, and methods of use thereof for delivering agents in vivo including nucleic acids and proteins. These compositions are not subject to accelerated blood clearance and they have an improved toxicity profile in vivo.Type: GrantFiled: August 10, 2017Date of Patent: February 11, 2020Inventors: Gilles Besin, Stephen Hoge, Joseph Senn, Kerry Benenato, Staci Sabnis
-
Patent number: 10485885Abstract: This disclosure provides improved lipid-based compositions, including lipid nanoparticle compositions, and methods of use thereof for delivering agents in vivo including nucleic acids and proteins. These compositions are not subject to accelerated blood clearance and they have an improved toxicity profile in vivo.Type: GrantFiled: December 21, 2018Date of Patent: November 26, 2019Assignee: ModernaTX, Inc.Inventors: Gilles Besin, Stephen Hoge, Joseph Senn, Kerry Benenato, Staci Sabnis
-
Publication number: 20190117798Abstract: This disclosure provides improved lipid-based compositions, including lipid nanoparticle compositions, and methods of use thereof for delivering agents in vivo including nucleic acids and proteins. These compositions are not subject to accelerated blood clearance and they have an improved toxicity profile in vivo.Type: ApplicationFiled: December 21, 2018Publication date: April 25, 2019Applicant: ModernaTX, Inc.Inventors: Gilles Besin, Stephen Hoge, Joseph Senn, Kerry Benenato, Staci Sabnis
-
Patent number: 10207010Abstract: This disclosure provides improved lipid-based compositions, including lipid nanoparticle compositions, and methods of use thereof for delivering agents in vivo including nucleic acids and proteins. These compositions are not subject to accelerated blood clearance and they have an improved toxicity profile in vivo.Type: GrantFiled: August 11, 2017Date of Patent: February 19, 2019Assignee: ModernaTX, Inc.Inventors: Gilles Besin, Stephen Hoge, Joseph Senn, Kerry Benenato, Staci Sabnis
-
Publication number: 20180328696Abstract: A device and method for aligning a sighting device with a reference. The device includes features conforming to an industry standard for attaching accessories to a firearm. The device contains features which allow the device to be leveled relative to a removable level. A sighting device may be attached to the device using the industry standard features. Once attached, the sighting device may then be aligned using either the removable level or an external reference. Once the sighting device is secured in its mount, the mounted sight may then be installed and removed from one or more devices without its calibrated orientation being altered.Type: ApplicationFiled: May 10, 2018Publication date: November 15, 2018Applicant: INVENTURE ENGINEERING AND MACHINE, LLCInventor: Anthony Joseph Senn
-
Publication number: 20180147298Abstract: This disclosure provides improved lipid-based compositions, including lipid nanoparticle compositions, and methods of use thereof for delivering agents in vivo including nucleic acids and proteins. These compositions are not subject to accelerated blood clearance and they have an improved toxicity profile in vivo.Type: ApplicationFiled: August 10, 2017Publication date: May 31, 2018Applicant: ModernaTX, Inc.Inventors: Gilles Besin, Stephen Hoge, Joseph Senn, Kerry Benenato, Staci Sabnis
-
Publication number: 20180028664Abstract: This disclosure provides improved lipid-based compositions, including lipid nanoparticle compositions, and methods of use thereof for delivering agents in vivo including nucleic acids and proteins. These compositions are not subject to accelerated blood clearance and they have an improved toxicity profile in vivo.Type: ApplicationFiled: August 11, 2017Publication date: February 1, 2018Applicant: ModernaTX, Inc.Inventors: Gilles Besin, Stephen Hoge, Joseph Senn, Kerry Benenato, Staci Sabnis
-
Patent number: 8568976Abstract: The present invention provides compositions and methods for identifying and utilizing proinflammatory nucleic acids. In particular, this invention relates to compounds, particularly oligonucleotides, which exert their effect through triggering receptors expressed by myeloid cells (TREMs), specifically TREM 2.Type: GrantFiled: December 12, 2011Date of Patent: October 29, 2013Assignee: Isis Pharmaceuticals, Inc.Inventor: Joseph Senn
-
Publication number: 20120295272Abstract: The present invention provides compositions and methods for identifying and utilizing proinflammatory nucleic acids. In particular, this invention relates to compounds, particularly oligonucleotides, which exert their effect through triggering receptors expressed by myeloid cells (TREMs), specifically TREM 2.Type: ApplicationFiled: December 12, 2011Publication date: November 22, 2012Applicant: Isis Pharmaceuticals, Inc.Inventor: Joseph Senn
-
Patent number: 8101345Abstract: The present invention provides compositions and methods for identifying and utilizing proinflammatory nucleic acids. In particular, this invention relates to compounds, particularly oligonucleotides, which exert their effect through triggering receptors expressed by myeloid cells (TREMs), specifically TREM 2.Type: GrantFiled: April 13, 2006Date of Patent: January 24, 2012Assignee: Isis Pharmaceuticals, Inc.Inventor: Joseph Senn